Mara Simopoulou, PhD
Associate Professor at National and Kapodistrian University of Athens , University of Athens
Primary ovarian insufficiency (POI) — also called premature ovarian failure — is a condition in women where the ovaries stop functioning normally before the age of 40. In such case, egg donation seems to be the only effective infertility treatment. But is it the only one? In this webinar, Dr Mara Simopoulou (Associate Professor of Experimental Physiology and Embryology at the Medical School of NKUA and Deputy Laboratory Manager of the Assisted Conception Unit at Aretaieio University Hospital) discussed novel medical approaches to addressing low ovarian reserve in assisted reproduction and answered patients’ questions.
Infertility is everyday reality for 1 out of 8 couples worldwide. According to Dr Mara Simopoulou, a considerable percentage of these couples are actually undergoing IVF treatment because of ovarian insufficiency. Undoubtedly, ovarian sufficiency is really challenging to manage. Dr Simopoulou says that one of the reasons for it is the lack of consensus and gold standard for doing it. Generally, the most common treatment to use is egg donation.
The ovaries are the primary female reproductive organs and they have an endocrine function and an exocrine function: they secrete hormones (such as estradiol) and are the ‘house’ of oocytes . Being the latter, they should support oocyte development and release mature oocytes in every menstrual cycle. However, the picture is not always so ideal.
Ovarian insufficiency is a term describing a wide range of pathopsychological conditions where ovarian function is compromised. And the reasons for it are really various. They can include maternal age, pathologies, surgeries and infections in the reproductive system, autoimmune diseases, mutations in genes implicated in the regulation of ovarian function and development (such as chromosomal and developmental abnormalities) or gonadoxic treatments (chemotherapy or radiotherapy). Dr Simopoulou admits that, apart from all that has been mentioned, there is also some data on ethnicity and how it affects ovarian insufficiency, e.g. Chinese, Latin and African women are of high risk for poor ovarian reserve. Last but not least – there is a woman’s lifestyle that can influence the functioning of her ovaries.
In the context of assisted reproductive technology (ART), women with ovarian insufficiency tend to produce oocytes of compromised quality and, as a result, they don’t have a high fertilisation rate in the IVF laboratory. POI patients may also be unable to ovulate normally and they not respond to ovarian stimulation protocols.
Dr Mara Simopoulou differentiates between two categories of ovarian insufficiency. The first one is when oocytes are being produced in low numbers and in most of cases, they are also of low quality. This category describes patients of poor ovarian response (the so-called ‘poor responders’) and perimenopausal women. The second category, on the other hand, refers to no folliculogenesis (meaning no oocyte production) and includes POI patients as well as the ones already in menopause.
According to Dr Simopoulou, there’s an ongoing debate in the scientific community on how to categorise the poor responders properly. On the basis of the 2011 Bologna-ESHRE criteria, at least two of the following features must be present to qualify a patient as a poor responder:
Despite that kind of clear distinction, one has to remember that poor responders are a very heterogeneous group of population. Luckily, in 2016 Poseidon criteria came along and helped scientists to subgroup these patients. Premature ovarian insufficiency, on the contrary, has a very strict definition – it is a cessation of menstruation in women under the age of 40. However, Dr Simopoulou reminds at this point that POI patients always have to be seen as a whole. In their case, it is not only infertility but there are also other issues involved. The latter refers to both menopausal symptoms (e.g. psycho-affective changes, vasomotor symptoms and urogynaecology and sexual changes) and long-term sequelae (auto-immune diseases, osteoporosis or accelerated cardiovascular disease).
There are two physiological processes that lead to ovarian insufficiency and that’s why POI patients can be divided into the pre-menopausal and menopausal ones. Perimenopause is the period preceding menopause and it can last for 5 to 7 years prior to menopause. During that time, there is a progressive reduction of ovarian function being observed and that manifests itself in menstrual cycle irregularities and mild vasomotor symptoms. The latter leads to the final stage – menopause. It is classified as least 12 months of calendar year of amenorrhea (not having periods) and cessation of folliculogenesis – the production of oocytes.
It is well-known that when women age, their fertility rate drops. In Dr Simopoulou’s opinion, it is one of the reasons why ovarian insufficiency is so challenging to deal with. One of the way of managing it is prevention – and it means oocyte cryopreservation. It is especially beneficial if a woman is below the age of 35.
However, the majority of women treated in IVF labs are between 35 and 45 years old. The most common method of dealing with such patients seems to be compensating for the average efficiency that is coming up. Up to recently, the approach was to maximise the ovarian response to the stimulation. The problem is that in case of ovarian insufficient patients, the response is generally poor – irrespectively of how much of a hard conventional stimulation protocol has been used. Dr Simopoulou says that nowadays there’s been a shift to rescuing oocyte competence and rejuvenating the ovary rather than trying to treat the symptoms. And this is where the novel approaches to ovarian insufficiency come into play: mitochondrial, spindle-chromosomal complex or pronuclear transfer, chromosome therapy, etc. They may be an alternative to the solution that is in common use today – meaning oocyte donation. It is not a surprise that the donation route is not an easy choice to make for many patients. In fact, what drives all these novel approaches is the patients’ will to explore all possible options for a genetically linked offspring.
Dr Simopoulou divides novel approaches to ovarian insufficiency into two categories. In the first one, we find those with the aim to restore the jeopardised ovarian micro-environment – and it means ovarian rejuvenation or ovarian function reactivation. This approach includes Platelet Rich Plasma (PRP) and stem cells. The other approach focuses on the oocytes rather than on ovaries and its aim is to restore oocyte quality and competence. This second scenario is all about Mitochondrial Replacement Therapy (MRT).
PRP is an autologous treatment, during which 30-60 ml of peripheral blood is drained from vein in a patient’s arm. Then this blood is centrifuged in order to end up with a concentrated version of plasma enriched with the patient’s own platelets. PRP consists of numerous proteins, such as cytokines, growth factors and hormones. The proteins serve as chemo-attractants for stem cells, macrophages and neutrophils which all contribute greatly to tissue regeneration. All the growth factors are considered responsible for cell migration and differentiation, as well as for proliferation, activation of angiogenesis and tissue regeneration. Because of all of that, PRP has emerged among the most innovative autologous blood products used to enhance tissue healing and regeneration. It has been used, among others, for tendonitis, nerve injuries, osteoarthritis skin rejuvenation and wound healing and fat grafting.
Dr Mara Simopoulou admits that it didn’t take long for certain fertility experts to start thinking how to turn all of the latter to their advantage and use PRP in the reproductive system. The pioneers behind the development of the intra-ovarian infusion of PRP treatment were Dr Konstantinos Pantos and Dr Konstantinos Sfakianoudis of Genesis Athens Clinic. They investigated the efficiency of the treatment in regards to the reactivation of dysfunctional ovarian tissue .
Dr Simopoulou describes the technique of PRP injection as an empirical approach, resembling the oocyte pick-up procedure. While the patient is under inhaled minimal sedation, her ovaries are visualised via transvaginal ultrasound monitoring and they are intramedullary injected on multiple sites. It is followed by the infusion of 4 ml of the prepared PRP mixture.
When it comes to the results, Dr Simopoulou says there are four randomised control trials run with the Genesis Athens Clinic at the moment and this is where the hard data and the proof are going to come from. But there are already some reports available and there are indications that PRP may effectively restore ovarian function in patients undergoing peri-menopause and menopause. It may also lead to cycle restoration, promote folliculogenesis and improve patients’ hormonal profile in the first 2-5 months following the treatment. But according to Dr Simopoulou, it is not just infertility that scientists are looking into in case of PRP.
As ovarian insufficiency leads to menopause-like symptoms that are jeopardising a woman’s well-being, addressing patients’ attitudes is crucial. Taking all of the latter into account, it has to be noted that PRP implementation certainly requires serious consideration regarding its biological efficiency and there is still more research data needed to come in. Dr Simopoulou’s conclusion is that PRP seems to work – but it does not work for every patient. That’s why the scientists’ main task today is to find out what is the profile of the patient that PRP works for.
Mesenchymal stem cells (MSCs) are known to migrate to damaged tissues and organs and differentiate to tissue-specific cells, promoting healing processes. They secrete a wide spectrum of growth factors, chemokines and mitogenic proteins and via these, they are able to promote proliferation and vascularisation. Besides, MSCs modulate immune response, present anti-inflammatory properties and exert anti-apoptotic properties limiting tissue degeneration. That’s why – like with PRP – it didn’t take long for fertility specialists to wonder if stem cell ovarian transplantation could restore the jeopardised ovarian micro-environment.
Dr Mara Simopoulou says there are a few studies available on autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. They bring a lot of conclusions but there are also questions that emerge, like whether it should be heterologous or autologous transplantation, if the treatment is safe and free of malignant transformation or what the best administration method is. The primary results from the studies indicate the stem cells are a promising approach. They may effectively restore ovarian function in patients with POI, POR and peri-menopause as well as promote folliculogenesis and improve patients’ hormonal profile. And all of this – in result – may enhance the reproductive outcome. But just like with PRP, the experimental status of the stem cell treatment is retained until there is further data from well-designed clinical trials available.
It is known that in order to achieve fertilisation and development, huge amounts of energy are required. And these are produced by the oocytes’ mitochondria. There is a proven association between mitochondrial DNA and poor oocyte quality and ovarian reserve. Dr Simopoulou highlights that the embryonic development up to day 5 heavily relies on mitochondria energy and the advancement of age corresponds to the reduction of functionality and number of oocytes’ mitochondria. That’s why the scientific community started to analyse whether replacing an older oocyte’s mitochondria with mitochondria from a younger oocyte would improve oocyte’s function. There are various techniques of performing the procedure being considered, such as heterologous/autologous germinal vesicle and spindle or pronuclear transfer. The latter is about moving the nuclear DNA from the patient’s oocyte right into the cytoplasm of the donor’s oocyte – after the removal of nuclear DNA from both oocytes. As a result, the donor egg is left with nuclear DNA from the mother and DNA from the donor.
Unfortunately, there is still a lack of robust or even adequate data indicating safety and effectiveness of the method. The European Society of Human Reproduction and Embryology (ESHRE) recommends extreme caution on the use of spindle transfer in human oocytes as a clinical application to address fertility problems. That is why Mitochondrial Replacement Therapy currently maintains its experimental status. Long-term follow-up of MRT is required in order to report on the safety and efficacy of the procedure.
Dr Mara Simopoulou is aware of the fact that the novel approaches to ovarian insufficiency that are under research nowadays used to sound like science-fiction 20 or even 10 years ago. That’s why the scientific community needs to be very careful with respect to where they’re heading with their work and, what is more, they have to consider what is it that drives the advances in assisted reproductive technologies. Although they perfectly realise there are extreme idiopathic cases in ART (that have no other alternative), they need to acknowledge the biological debate and experimental stages that some of the novel techniques are facing. The only way to make patients feel safe is to move forward with proper research methodologies and provide the randomised control trial data prior to the possible application of any of these techniques in large number of patients.
You may be interested in reading more about:
- Questions and AnswersDisclaimer:
Informations published on myIVFanswers.com are provided for informational purposes only; they are not intended to treat, diagnose or prevent any disease including infertility treatment. Services provided by myIVFanswers.com are not intended to replace a one-on-one relationship with a qualified health care professional and are not intended as medical advice. MyIVFanswers.com recommend discussing IVF treatment options with an infertility specialist.
Contact details: The European Fertility Society C.I.C., 2 Lambseth Street, Eye, England, IP23 7AGNecessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors. |
_gat_UA-38575237-21 | 1 minute | No description |
_gid | 1 day | This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form. |
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Cookie | Duration | Description |
---|---|---|
_gat_FSQM52 | 1 minute | No description |
cf_ob_info | No description | |
cf_use_ob | No description |